Drugs / elivaldogene tavalentivec
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01896102 | Aug 2013 → Mar 2021 | X-linked cerebral adrenoleukodystrophy | Genetix Biotherapeutics Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03852498 | Jan 2019 → Jul 2023 | X-linked cerebral adrenoleukodystrophy | Genetix Biotherapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | elivaldogene tavalentivec | “The investigational therapy involved infusion of autologous CD34+ cells transduced with the elivaldogene tavalentivec (Lenti-D) lentiviral vector.” PMID 28976817 ↗ Oct 2017 |
| Known as | Elivaldogen tavalentivec | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990046 ↗ |
| Known as | Lenti-D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01896102 ↗ |
| Known as | Lenti-D Drug Product | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990046 ↗ |
| Route | Intravenous | “Participants received a single intravenous (IV) infusion of Lenti-D Drug Product” NCT01896102 ↗ |
| Target | ABCD1 | “lentiviral vector encoding ABCD1 cDNA for human adrenoleukodystrophy protein” NCT01896102 ↗ |